Abstract Cis-dichloro palladium(II) and platinum(II) complexes (2, 4) of the general formula Mass-and IR-spectroscopy. The cytotoxic effect of these complexes against MDA-231 and MCF-7 human breast cancer cell lines and K562 human leukemia cell line has been studied.
Introduction
The similarity between the coordination chemistry of palladium(II) and platinum (II) compounds has led to a large research effort towards Pd(II) antitumor drugs that are efficient against Pt(II) resistant therapies and have less side effects [1] . A key factor that might explain why platinum is most useful comes from the ligand-exchange kinetics. The hydrolysis in palladium complexes is too rapid; 10 5 times faster than that of the corresponding platinum analogues [2] . These complexes dissociate readily in solution leading to very reactive species that are unable to reach their pharmacological targets. Accordingly, compared to cisplatin, the corresponding cis-palladium, cis-[PdCl 2 (NH 3 ) 2 ] does not show antitumor activity [3] .
Therefore, if an antitumor palladium complex is to be designed, it must be stabilized by a chelate or a strongly coordinating nitrogen ligand [4] .
Studies of platinum and palladium compounds with biologically active carriers have yielded promising results in the field of anticancer chemistry and there is potential for varying the biological activity of these complexes by changing the structure of the carrier [5] . Significant advances have emerged from this methodology of design [6] .
Previously, we reported the synthesis and molecular structure of an enantiometrically pure, 2 ] that bears the bulky amine ligand R-(+)-bornylamine (endo-(1R)-1,7,7-trimethylbicyclo[2-2-1]-heptan-2-amine) [7] . The complex showed similar antitumor activity against HeLa cells when compared with the activity of the standard references, cisplatin, carboplatin and oxaliplatin. In addition, a palladium complex which contains the bulky nitrogen ligand harmine (7-methoxy-1-methyl-
trans-palladium(II) complex, trans-[PdCl 2 {(R)-(+)-bornyl-amine}
] exhibited a greater cytotoxic activity against P388, L1210 and K562 cell lines than cisplatin [8] .
Connors et al. [9] and Meischen et al. [10] have reported different platinum(II) complexes with aromatic amines, such as cis-dicloro(4-chloro-1,2-phenylenediamine)platinum(II) and cisdicloro(1,2-phenylenediamine)platinum(II). Although these complexes were less active than cisplatin, they have showed relevant biological activity against the L1210 leukemic cell lines.
De Almeida et al. also reported that platinum(II) complexes with ligands derived from 1,2-phenylenediamine have potential cytotoxicity [11] . The evaluated compounds were less active in vitro than cisplatin. Cytotoxic evaluation results suggested that the presence of the strong electron-withdrawing group in the aromatic ring lead to a decrease in the cytotoxicity against human cancer cell lines such as MCF7 and EVSAT (mammary cancers), WiDr (colon cancer),) and H226 (lung cancer). as anticancer agents and bactericides [12] . Furthermore, ferrocenyl-based complexes with 5-fluoro-6-(4-substitutd-1-piperazyl)benzimidazoles have been reported. These complexes were
shown to have potency comparable to that of azole-based antifungal agents (Miconazole) [13] .
It seems that the benzimidazoles with both, fluorine and piperazine as substituents lead to a considerable enhancement of the antibacterial potency [14] . The substituted 1-piperazinyl derivative belongs to a group of DNA binding fluorochromes used in chromosome staining and some of them exhibit antihistaminic activity [15] .
It was proposed that a combination between Pd(II) or Pt(II) with 4-fluoro-5-(4-piperazinyl)-1,2-diaminobenzene could led to the formation of compounds with potent antitumor activity.
Up to our knowledge, as we are aware, no study of palladium(II) and platinum(II) complexes containing 4-fluoro-5-(4-piperazinyl)-1,2-diaminobenzene was reported.
As an extension of our studies on both the coordination chemistry of heteroatom containing ligands [16] and on the biological activity [17, 18] of their metal complexes, we describe here the synthesis and characterization of new square-planar platinum(II) and palladium(II) complexes bearing the bidentate chelate, 1,2-diamino-4-fluoro-5-(4-methyl)-1-piperazinyl benzene (DAFPB). For comparison purposes, the biological activity of the corresponding water soluble, dicationic, diacetonitrile palladium(II) complex was also investigated. The aim of our study was to investigate the influence of DAFPB as a biologically active carrier on the cytotoxic properties of the platinum(II) and palladium(II) complexes against MDA-231 and MCF-7 human breast cancer cell lines and K562 leukemia cell line.
Experimental

Materials and Instrumentation
The complex [Pd(NCCH 3 ) 4 ](BF 4 ) 2 was purchased from Aldrich. Reagent grade chemicals were used as received unless otherwise stated. 1,2-diamino-4-fluoro-5-(4-methyl-1-piperazinyl) benzene was prepared as previously described [19] . Elemental analyses were performed using a (EURO EA 3000 instrument). 1 H-NMR spectra were recorded on a Bruker spectrometer operating at 300 MHz using DMSO-d 6 as a solvent with TMS as an internal standard. Infrared spectra (KBr discs) were measured on a Nicolet-Magna-IR 560 Spectrophotometer. Mass spectra (EI) were acquired using a Shimadzu-QP5050A. Melting points were measured by a Stuart Scientific melting Apparatus (uncorrected ± 0.1 °C).
Synthesis of complexes
A filtered solution of the ligand (1) 
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P . Cells were kept in a humified 5% COR 2 R incubator at 37 P according to Alverdi et al. [22] and Franken et al. [23] .
Results and Discussion
Chemistry
The palladium(II) (2) and platinum(II) (4) [24] .
The isolated compounds are microcrystalline or powder-like and stable at atmospheric conditions. The new compounds have been characterized using variety of techniques including elemental analysis, IR-, mass-(EI), and 1 H-NMR-spectroscopy.
Scheme 1. Synthesis of the complexes used in the present study (2-4)
Elemental analyses of the complexes (2) (3) (4) showed that the metal to the fluoro-piperazinyl ligand ratio in the dichloro complexes is 1:1. The presence of the ligands in the complexes was also confirmed by IR-analyses ( Table 1 ). The peaks due to the stretching vibration of the amine (N-H) showed slight shift to higher frequency. This slight stiffness of vibration refers to complexation of the ligands with the metal (Table 1) . Although some of the complexes were microcrystalline, attempts to obtain crystals of suitable quality for an X-ray structure determination were unsuccessful and could be due to the marginal solubility of the dichloride complexes. Therefore, only the solution behavior of complex 3 was determined by NMR spectroscopy in DMSO-d 6 at room temperature. The 1 H-NMR experiments showed that the metal to ligand ratio is 1:1. It has been indicated that slight shift to higher delta values of the ligand signals is observed upon coordination with palladium. 
Biological investigations
The cytotoxic activities of the ligand (1) and the corresponding complexes (2-4) were evaluated against human MDA-231 breast cancer cell line, human MCF-7 breast cancer cell line and human K562 leukemia cell line. The results are shown in Table 2 in terms of IC 50 values (the concentration needed to inhibit 50% of the cellular proliferation). For comparison purposes, the cytotoxicity of cisplatin, a standard antitumor drug, was tested under the same conditions.
The obtained data (Table 2) showed the highest activity among the compounds investigated in the present study. In addition, the organic carrier (ligand, DAFPB, 1) showed substantial activity compared with the standard antitumor drug, cisplatin and the platinum(II) complex (4) against MDA-231 and MCF-7 human breast cancer cell lines. The noticeable activity of the organic ligand could be due to the presence of the piperazinyl moiety. Previous investigation showed that the presence of a strong electron-withdrawing group in the aromatic ring lead to a decrease in the cytotoxic activity of platinum(II) complexes [11] .
However, the platinum(II) complex, [(DAFPB)PtCl 2 ] (4) is more active than cisplatin against only MDA-231 breast cancer and human K562 leukemia cell lines. The corresponding dicationic complex (3) showed higher cytotoxic activity compared with cisplatin and the ligand only against K562 leukemia cell line.
According to Table 2 , metalltion of the organic biological carrier with palladium significantly increases its biological activity towards all cancer cell lines. However, the corresponding platinum(II) complex showed lower activity than compounds, 1 and 2. This behavior could be due to the relatively lower rate of hydrolysis of the palladium (II) complex caused by the coordination with the ridged aromatic diamine ligand (1). However, due to the relatively lower stability of the dicationic complex (3), the activity towards human MCF-7 breast cancer cell declined. Table 2 MTT results, the values shown are the IC 50 .
Based on the cytotoxic activity results above, it seems that both electronic properties and bulkiness of the ligand have a noticeable influence not only on the activity of the palladium(II) but also on its stability. The anti-proliferative activity of the new complexes was also evaluated by studying the effect on clonal growth capacity of cells (Figure 1 A-C) . The obtained data suggest that the palladium derivatives show a significant anti-proliferative activity similar to that of the reference drug (cisplatin). 
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